MedTrace Logo

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

NCT00082082 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-01-15

No results posted yet for this study

Summary

The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Thymalfasin (thymosin alpha-1)

PROCEDURE

Trans arterial chemoembolization (TACE)

Sponsors & Collaborators

  • SciClone Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00082082 on ClinicalTrials.gov